Evidence map›Paper›PMID 27132279›Full record

ReviewHaematologica2016

Role of the tumor microenvironment in mature B-cell lymphoid malignancies.

Nathan H Fowler, Chan Yoon Cheah, Randy D Gascoyne, John Gribben, Sattva S Neelapu, Paolo Ghia, Catherine Bollard, Stephen Ansell, Michael Curran, Wyndham H Wilson and 6 more

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Haematologica, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 63 papers.

0numbers the graph read from it
0cells of the map it votes in
63citing papers in PubMed
4.7field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

63 citing papers in PubMed, 109 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Trial
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Article
  11. Tumor microenvironment as a complex milieu driving cancer progression: a mini review.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2025
    Review
  12. Review
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Review
  19. Article
  20. Review

3 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 8 institutions in 5 countries.

Nathan H FowlerDepartment of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA nfowler@mdanderson.org.
Chan Yoon CheahDepartment of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA Department of Haematology, Pathwest Laboratory Medicine WA and Sir Charles Gairdner Hospital, Perth, Western Australia University of Western Australia, Perth, Canada.
Randy D GascoyneBritish Columbia Cancer Research Centre, Vancouver, British Columbia, Canada.
John GribbenDepartment of Haemato-Oncology, Barts Cancer Institute, London, UK.
Sattva S NeelapuDepartment of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Paolo GhiaUniversità Vita-Salute San Raffaele, Division of Experimental Oncology, IRCCS Istituto Scientifico San Raffaele, Milan, Italy Department of Onco-Hematology, Ospedale San Raffaele, Milan, Italy.
Catherine BollardChildren's Research Institute, Washington, DC, USA.
Stephen AnsellDivision of Hematology, Mayo Clinic, Rochester, MN, USA.
Michael CurranDepartment of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Wyndham H WilsonLymphoid Malignancies Branch, National Cancer Institute, Bethesda, MD, USA.
Susan O'BrienUniversity of California, Irvine, CA, USA.
Cliona GrantSt. James' Hospital, Dublin, Ireland.
Richard LittleCancer Therapeutic Evaluation Program, National Cancer Institute, Bethesda, MD, USA.
Thorsten ZenzUniversity of Heidelberg, Germany.
Loretta J NastoupilDepartment of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Kieron DunleavyLymphoid Malignancies Branch, National Cancer Institute, Bethesda, MD, USA.
The University of Texas MD Anderson Cancer Center · USNational Cancer Institute · USChildren’s Institute · USHeidelberg University · DEMayo Clinic in Arizona · USSt. James's Hospital · IEUniversity of California, Irvine · USVita-Salute San Raffaele University · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The tumor microenvironment is the cellular and molecular environment in which the tumor exists and with which it continuously interacts. In B-cell lymphomas, this microenvironment is intriguing in that it plays critical roles in the regulation of tumor cell survival and proliferation, fostering immune escape as well as the development of treatment resistance. The purpose of this review is to summarize the proceedings of the Second Annual Summit on the Immune Microenvironment in Hematologic Malignancies that took place on September 11-12, 2014 in Dublin, Ireland. We provide a timely overview of the composition and biological relevance of the cellular and molecular microenvironment interface and discuss the role of interactions between the microenvironment and neoplastic cells in a variety of B-cell lymphomas. In addition, we focus on various novel therapeutic strategies that target the tumor microenvironment, including agents that modulate B-cell receptor pathways and immune-checkpoints, chimeric antigen receptor T cells and immunomodulatory agents.

Indexed as

Tumor MicroenvironmentAnimalsBiomarkersB-LymphocytesDrug Resistance, NeoplasmGene Expression Regulation, NeoplasticHumansImmunotherapyLeukemia, B-CellLymphoma, B-CellMolecular Targeted TherapyNeoplasm GradingNeoplasm StagingSignal TransductionTumor EscapeBiomarkers

Identifiers

PMID27132279
PMCPMC5004369
OpenAlexW2343596911

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.